Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Myeloproliferative neoplasms (incl. CML)
Stage/Subtype:  chronic neutrophilic leukemia
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 43 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Busulfan, Fludarabine Phosphate, Total-Body Irradiation, and Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: HEM-05011-L, NCI-2013-00779, CDR0000447204, OHSU-210, OHSU-HEM-05011-L, NCT00245037
Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 70
Trial IDs: 2005-0781, NCI-2011-02823, RP100469 02, NCT00498316
Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF)
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: KB004-01, NCI-2011-00883, NCT01211691
Donor Cytokine-Induced Killer Cells in Treating Patients with Myelodysplasia or Myeloproliferative Disorders Previously Treated with Donor Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 50 and over
Trial IDs: BMT217, NCI-2011-01493, SU-04202010-5724, NCT01392989
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Age: Under 75
Trial IDs: 1825.00, NCI-2010-00230, FHCRC-1825.00, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
Mismatched Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase: Phase II
Type: Treatment
Age: 18 to 65
Trial IDs: IUCRO-0184, NCI-2011-02351, NCT00593554
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, NCT00968630
Rasburicase or Allopurinol in Preventing Tumor Lysis Syndrome in Patients with Hematological Malignancies Undergoing Chemotherapy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 2010-0284, NCI-2012-01889, NCI-2010-02082, NCT01200485
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Two Step Donor Stem Cell Transplant in Treating Patients With High-Risk Hematological Malignancies
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 08D.85, NCI-2012-00407, 2007-61, NCT01315132
Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11D.247, NCI-2011-02345, 1795, 2011-31, NCT01384513
Fludarabine Phosphate, Melphalan, and Total-Body Irradiation before Donor Double Umbilical Cord Blood Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 11-085, NCI-2012-00147, NCT01408563
Bulk or Fractionated Stem Cell Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II
Type: Treatment
Age: Under 75
Trial IDs: 12-016, NCI-2012-00824, NCT01596257
Ruxolitinib Phosphate in Treating Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10262, NCI-2014-00633, NCT02092324
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378AUS23, NCI-2014-02128, NCT02186821
Pasireotide in Reducing Gastrointestinal Toxicity from Chemotherapy and Radiation in Patients Undergoing a Donor Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: Pro00051736, NCI-2014-02316, NCT02215070
Cyclophosphamide, Fludarabine Phosphate, and Donor White Blood Cells Treating Patients With Hematologic Malignancies That Relapsed After a Previous Donor Stem Cell Transplant
Phase: Phase II
Type: Treatment
Age: 1 and over
Trial IDs: MT2003-15, NCI-2010-01695, 2004LS006, NCT00303693, NCT00167180
T-cell Depleted Stem Cell Boost in Improving Graft Function in Patients Who Have Undergone Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 14-228, NCI-2015-00179, NCT02350777
Sirolimus or Vorinostat in Combination with Hydroxychloroquine in Treating Patients with Advanced or Metastatic Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2010-0588, NCI-2011-00303, NCT01266057
Start Over